ATR Inhibitor-Based Combination Treatments in the Clinic: Biomarkers for Patient Selection

Time: 8:30 am
day: Day Two


  • ATM remains the most studied biomarker for ATRi monotherapy activity and also for ATRi-DDRi combinations
  • Explore how replication stress signatures represent an emerging biomarker, but not ready for prime time yet
  • Learn how to optimally select patients for PARPi-ATRi in both the PARPi naïve and resistant settings remains a challenge